You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Microfluidic DNA Sequencing
SBC: GNUBIO, INC. Topic: NHGRIDESCRIPTION (provided by applicant): This is a Phase II SBIR proposal to increase the throughput of our DNA sequencing instrument to enable whole genome sequencing with high efficiency and accuracy for a cost of under 1000 per genome. In Phase I, we developed a working sequencing assay, a microfluidic platform and camera system, and analysis methodology that enable genome alignment and variant ca ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin
SBC: THERMALIN DIABETES, INC. Topic: NIDDKDESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( smart pumps ). A proprietary approach is proposed basedon the favorable physico-chemical properties conferred by chloro-aromatic substitutions in the insulin molecule. This Phase 2 SBIR application th ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
RandD- MEDICAL: BIOMEDICAL (BASIC RESEARCH)
SBC: IMMUNETICS, INC. Topic: NHLBIThis project is aimed at the development of an enzyme immunoassay (ELISA) for screening blood for antibodies to Babesia microti. Human babesiosis is a malaria-like illness due to infection of red blood cells by various species of protozoan parasites belonging to the genus Babesia. Most human infections reported in the United States are caused by B. microti which is endemic in parts of the northeas ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
ChNKG2D-Targeted Cellular Cancer Therapy: Phase I Clinical Trial
SBC: CELDARA MEDICAL, LLC Topic: NHLBIDESCRIPTION (provided by applicant): The global burden of cancer doubled between 1975 and 2000. Cancer became the leading cause of death worldwide in 2010, and is projected to double again by 2020 and to triple by 2030. This horrible disease has touched each of us, and despite enormous investments in prevention and treatment, its impact continues to accelerate. Ideally, any cancer therapy should ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Pre-clinical Development of a Context-Dependent NMADR Neuroprotectant for Treatme
SBC: NEUROP, INC. Topic: 102DESCRIPTION provided by applicant Cerebral ischemia is a major cause of death and long term disability with high accompanying social and medical costs Approximately Americans suffer a stroke each year at an estimated annual cost of $ B American Heart Association Heart Disease and Stroke Statistics Update Substantial preclinical data support the use of NMDA receptor antago ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea
SBC: SELEXYS PHARMACEUTICALS CORPORATION Topic: NHLBIDESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance SelG1 into Phase II/III safety and efficacy trials to support of regulatory filings for FDA approval ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
IMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINE
SBC: SANARIA INC. Topic: NIAIDDESCRIPTION (provided by applicant): The development of Sanaria's aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoite (SPZ)-based products has received international recognition during the past year, due principally to four findings: 1)PfSPZ Challenge (infectious PfSPZ) induced malaria in volunteers, 2) PfSPZ Vaccine (radiation attenuated PfSPZ) induced unprecedented levels ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
A fully integrated assay and platform for detecting Clostridium difficile.
SBC: CLAREMONT BIOSOLUTIONS LLC Topic: NIAIDDESCRIPTION (provided by applicant): The primary goal of this proposed project is to develop a point-of-care diagnostic assay and platform for the detection of Clostridium difficile from human stool. Two additional goals are to detect the hypervirulent strain of C. difficile B1/NAP/027 and to detect C. difficile spores from swabs of medical devices. C. difficile associated disease (CDAD) is now th ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of RLIP76 protein as a Radiation Countermeasure
SBC: TERAPIO Topic: NIAIDDESCRIPTION (provided by applicant): There remains a critical need for medicines that can counteract the toxic effects of radiation exposure. Terapio is developing a recombinant protein, RLIP76, for use as a radioprotectant for workers, military personnel, or civilians that are either in imminent danger of radiation exposure, or have already been exposed. In research carried out at the Unive ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
A Rapid Point-of-care Diagnostic for C. trachomatis STDs
SBC: NetBio, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Improved diagnosis of Chlamydia trachomatis (Ct) infections represents a critical unmet medical need. Ct is the most common cause of bacterial sexually transmitted diseases (STD) worldwide, and the Centers for Disease Control and Prevention estimate that there are 2.8 million US cases annually. Currently, 40% of women with untreated infection will develop pelvi ...
SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health